Dodecyl Creatine Ester - CERES BRAIN Therapeutics
Alternative Names: CBT-101 - CERES BRAIN Therapeutics; Dodecyl creatine ester hydrochloride - CERES BRAIN TherapeuticsLatest Information Update: 25 Apr 2024
At a glance
- Originator CERES BRAIN Therapeutics
- Class Acetates; Urea compounds
- Mechanism of Action Creatine replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mitochondrial disorders; X-linked creatine deficiency
Most Recent Events
- 24 Apr 2024 Preclinical trials in Mitochondrial disorders in France prior to April 2024 (Intranasal) (Ceres Brain therapeutics pipeline, April 2024)
- 22 Apr 2022 Preclinical trials in X-linked creatine deficiency in France (Intranasal) (CERES BRAIN Therapeutics website, April 2022)
- 03 Sep 2021 CBT 101 - CERES BRAIN Therapeutics receives Orphan Drug status for X-linked creatine deficiency in USA